Information Provided By: 
Fly News Breaks for February 27, 2020
ZGNX
Feb 27, 2020 | 14:38 EDT
William Blair analyst Tim Lugo maintained an Outperform rating on Zogenix (ZGNX), and has a $57 fair value estimate on shares. The analyst noted that this morning, Zogenix announced a three-month extension of the review period of the NDA for Fintepla for the treatment of Dravet syndrome, or DS, with a new PDUFA target action date of June 25, 2020, delayed from March 25, 2020. Lugo said that while this delay is "another setback" for the company, he is "cautiously optimistic" of an approval in the EU in Q1 followed by a U.S. approval in Q2.
News For ZGNX From the Last 2 Days
There are no results for your query ZGNX
